Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network

Li-Tzy Wu¹,²
Walter Ling³
Bruce Burchett¹
Dan G Blazer¹,²
Jack Shostak²
George E Woody⁴

¹Department of Psychiatry and Behavioral Sciences, School of Medicine, ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; ³David Geffen School of Medicine, NPI/Integrated Substance Abuse Programs, University of California, Los Angeles, CA, USA; ⁴Department of Psychiatry, School of Medicine, University of Pennsylvania and Treatment Research Institute, Philadelphia, PA, USA

Purpose: Detoxification often serves as an initial contact for treatment and represents an opportunity for engaging patients in aftercare to prevent relapse. However, there is limited information concerning clinical profiles of individuals seeking detoxification, and the opportunity to engage patients in detoxification for aftercare often is missed. This study examined clinical profiles of a geographically diverse sample of opioid-dependent adults in detoxification to discern the treatment needs of a growing number of women and whites with opioid addiction and to inform interventions aimed at improving use of aftercare or rehabilitation.

Methods: The sample included 343 opioid-dependent patients enrolled in two national multisite studies of the National Drug Abuse Treatment Clinical Trials Network (CTN001-002). Patients were recruited from 12 addiction treatment programs across the nation. Gender and racial/ethnic differences in addiction severity, human immunodeficiency virus (HIV) risk, and quality of life were examined.

Results: Women and whites were more likely than men and African Americans to have greater psychiatric and family/social relationship problems and report poorer health-related quality of life and functioning. Whites and Hispanics exhibited higher levels of total HIV risk scores and risky injection drug use scores than African Americans, and Hispanics showed a higher level of unprotected sexual behaviors than whites. African Americans were more likely than whites to use heroin and cocaine and to have more severe alcohol and employment problems.

Conclusions: Women and whites show more psychopathology than men and African Americans. These results highlight the need to monitor an increased trend of opioid addiction among women and whites and to develop effective combined psychosocial and pharmacologic treatments to meet the diverse needs of the expanding opioid-abusing population. Elevated levels of HIV risk behaviors among Hispanics and whites also warrant more research to delineate mechanisms and to reduce their risky behaviors.

Keywords: buprenorphine, clinical trials network, gender differences, health disparity, HIV risk behavior, methadone, opioid dependence, rehabilitation

Introduction

Opioid use disorders comprise the second most prevalent drug use disorder in the US, following marijuana use.¹ Recent evidence indicates that opioids are associated with the highest rate of drug-related overdose² and account for the highest proportion of drug-related admissions to treatment facilities that receive public funds.³ When taking into account specific substances, heroin users are most likely to enter substance abuse treatment, and nonmedical prescription opioid users show the highest rate of
increase among those seeking treatment. Heroin addiction has been the central target for opioid dependence treatment, with methadone as the primary treatment medication. However, the rising rate of prescription opioid abuse has added heterogeneity to the profile of individuals needing treatment and treatment options. The Drug Addiction Treatment Act of 2000 approved office-based treatment with buprenorphine. For the first time, physicians can prescribe an opioid-based treatment for opioid-dependent patients in their usual practice setting. Unlike methadone treatment, which is administered in specially licensed programs and requires almost daily attendance at treatment initiation, buprenorphine treatment allows patients to self-administer by prescription, thereby enhancing treatment use by individuals who otherwise are reluctant to seek treatment from methadone programs.

Given the increasing need for effective opioid detoxification, the first two national Clinical Trials Network studies examined the effectiveness of buprenorphine (Suboxone, Reckitt Benckiser Pharmaceuticals Inc, Richmond, VA) for short-term opioid detoxification in inpatient and outpatient settings. Because treatment options increase in parallel with the growing number of opioid-abusing individuals, research is needed to characterize clinical needs of various groups of treatment-seeking individuals and to inform newer treatment strategies. Specifically, opioid-abusing individuals are becoming increasingly diverse, eg, women and whites represent a growing group, while patients with heroin addiction tend to be older African Americans. Moreover, recent data suggest an increased rate of heroin injection among young white adults and a declining rate among young African American adults.

Short-term opioid detoxification is a frequent treatment for initiating abstinence and often serves as an initial contact for treatment. In 2007, 38% of heroin admissions and 30% of nonheroin opioid admissions to the US Treatment Episode Data Set received detoxification treatment. Therefore, detoxification represents a window of opportunity for engaging patients in aftercare or rehabilitation, a crucial element to prevent relapse and achieve recovery. However, there is limited information concerning clinical profiles of individuals seeking detoxification, and the opportunity to engage patients in detoxification for aftercare often is missed. For example, data from employer health insurance claims show that only 49% of detoxification episodes were followed by continuing aftercare within 30 days of discharge. Evidence from a large public sector dataset indicates that 27% of the sample was readmitted for detoxification within a year.

Given the expansion of a diverse opioid-dependent population, there is a clear need to discern clinical profiles of patients seeking detoxification to inform interventions aimed at improving aftercare use and reducing relapse. Prior research has focused on primary heroin users in methadone treatment programs drawn from one site. Due to the short-term nature of detoxification, there is a lack of systematic research to characterize clinical needs of various groups of patients seeking detoxification. To address this gap, this study capitalizes on the wealth of baseline data of patients who participated in multisite detoxification clinical trial studies to examine the extent of gender and racial differences in substance use, addiction severity, human immunodeficiency virus (HIV) risk, and quality of life. The goal is to describe patient differences better so that treatment for opioid addiction and interventions aimed at promoting aftercare use and rehabilitation can be improved. This study extends from prior studies by, first, examining a geographically diverse sample of opioid-dependent adults recruited from two treatment modalities at 12 programs to enhance its generalizability; second, elucidating gender and racial differences in clinical needs owing to an increased number of women and whites with opioid addiction; and, third, focusing on patients seeking detoxification, who represent an understudied group of opioid-dependent individuals as compared with patients in methadone treatment programs.

**Methods**

**Data source**

Analyses were performed on the data from two multisite National Drug Abuse Treatment Clinical Trials Network studies that evaluated the effectiveness of buprenorphine-naloxone and clonidine for opioid detoxification in inpatient (n = 113) and outpatient (n = 230) community-based treatment programs. Inpatients were recruited from six programs located in eastern, southeastern, midwestern, or western regions of the US; outpatients were recruited from six programs located in eastern, midwestern, or western regions of the US. Eligible patients included treatment-seeking adults aged ≥18 years who met Diagnostic and Statistical Manual, Version IV criteria for opioid dependence and were in need of medical management for opioid withdrawal. The use of the trials’ data for this study was approved by the Duke University Institutional Review Board.

Patients were excluded if they: had a serious psychiatric or medical condition that would make participation medically hazardous (eg, suicidal behavior, uncontrolled diabetes); had a known allergy or sensitivity to buprenorphine, naloxone, or...
clonidine; were receiving medications contraindicated with clonidine or had a systolic blood pressure <100 mmHg or pulse <56 beats per minute; had been enrolled in a methadone treatment program or had participated in another investigational drug study within 30 days of study enrollment; or could not remain in the area for the duration of active treatment. To enhance the study’s generalizability, dependence on other drugs did not exclude individuals from participation unless immediate medical attention was required to manage these disorders. Female participants were excluded if pregnant or lactating and were required to have a negative pregnancy test prior to randomization.

**Study variables**

Demographic variables included age, gender, race/ethnicity (non-Hispanic white, non-Hispanic African American, Hispanic, and other [Asian or Native American]), education, marital status, and employment status. Addiction Severity Index assessed substance use-related problems at intake in alcohol use, drug use, medical, psychiatric, legal, family/social, and employment domains. Each Addiction Severity Index composite score (range 0–1) is mathematically derived to summarize responses to several questions within a problem area, with higher composite scores indicating greater problem severity. Scores have demonstrated reliability and validity.

Questions on current (past-month) substance use from the Addiction Severity Index were examined to determine specific substance use, including nicotine/tobacco products, alcohol to intoxication (at least three drinks in one sitting or at least five drinks in one day), heroin, other opioids, sedatives/tranquilizers, marijuana, inhalants, hallucinogens, cocaine, and amphetamines. Because very few patients used hallucinogens or inhalants (<1%), they were not examined in the subsequent analysis.

HIV risk was assessed by the HIV Risk Behavior Scale, an instrument with demonstrated reliability and construct validity in drug users. It assesses behaviors involving injection drug use (needle sharing, use of unclean needles) and unprotected sex (multiple sexual partners, condom use) in the past 30 days. Responses to each item were coded on a six-point scale (0–5), with higher values associated with more risky behaviors. Three summary scores were examined, ie, total HIV risk, injection drug use risk, and sexual risk.

Quality of life was assessed by the SF-36, a reliable and valid subject-administered instrument. It measures health-related quality of life in physical functioning, role limitations due to physical health problems, role limitations due to emotional problems, energy/vitality, emotional well-being, social functioning, bodily pain, and general health perceptions. A high score indicates better functioning.

**Data analyses**

Bivariate associations of each study variable with gender and race/ethnicity were determined using $\chi^2$ test for proportions and $F$ test for continuous variables. To reduce the chance of false positive associations, only variables associated with gender ($P \leq 0.05$) from bivariate analyses were examined in the adjusted analyses. A more conservative $P$ value ($P \leq 0.09$) was used to select variables for adjusted analysis of the race/ethnicity variable due to reduced power for identifying racial/ethnic differences. Finally, adjusted logistic regression procedures (for categorical variables) and linear regression procedures (for continuous variables) were conducted to estimate differences in substance use, Addiction Severity Index, HIV risk, and quality of life in relation to gender and racial/ethnic backgrounds. Each model controlled for potential confounding influences from age, years of education, marital status, employment status, and treatment modality (inpatient versus outpatient).

**Results**

**Characteristics of opioid-dependent patients**

The mean age and years of education of the study sample were 37.5 years and 12.6 years, respectively (Table 1). Within

| Table 1 Selected characteristics of adult patients in opiate detoxification treatment ($n = 343$) |
|----------------------------------------------------------|
| Demographics | Total |
| Age, mean (SD) | 37.5 (10.16) |
| Years of education, mean (SD) | 12.6 (2.06) |
| Gender, n (%) | | |
| Male | 233 (67.9) |
| Female | 110 (32.1) |
| Race/ethnicity, n (%) | | |
| White | 155 (45.2) |
| African American | 106 (30.9) |
| Hispanic | 69 (20.1) |
| Other | 13 (3.8) |
| Marital status, n (%) | | |
| Married or cohabitating | 94 (27.4) |
| Separated, divorced, or widowed | 89 (26.0) |
| Never married | 160 (46.7) |
| Past month employment, n (%) | | |
| Employed | 169 (49.3) |
| Unemployed/not employed | 174 (50.7) |
| Treatment modality, n (%) | | |
| Inpatient detoxification | 113 (32.9) |
| Outpatient detoxification | 230 (67.1) |

**Abbreviation:** SD, standard deviation.
the sample, 32% were female, 55% were nonwhite (African American 31%, Hispanic 20%, other 4%), 47% had never being married, and 49% were employed.

**Gender differences in substance use problems, HIV risk, and quality of life**

Bivariate associations of specific substance use, Addiction Severity Index subscales, HIV risk, and quality of life with gender are summarized in Table 2. Men were more likely than women to have used heroin in the past month (94% versus 81%) and to have more severe alcohol use and legal problems. Women were more likely than men to have used other opioids (44% versus 22%) and sedatives/tranquilizers (32% versus 19%) in the past month, have more severe psychiatric and family/social problems, and report poorer quality of life in vitality, emotional well-being, and social functioning. There were no gender differences in HIV risk scores.

**Table 2** Substance use, addiction severity (ASI), HIV risk (HRBS), and quality of life (SF-36) by gender among adult patients in opiate detoxification treatment (n = 343)

| Study variables                          | Male (n = 233) | Female (n = 110) | P valuea |
|------------------------------------------|----------------|-----------------|----------|
| Past month substance use, %              |                |                 |          |
| Alcohol use to intoxication              | 20.6           | 16.4            | 0.35     |
| Heroin                                   | 94.0           | 80.9            | <0.01    |
| Other opioids                            | 22.3           | 43.7            | <0.01    |
| Sedatives/tranquilizers                  | 18.5           | 31.8            | <0.01    |
| Cocaine                                  | 47.6           | 37.3            | 0.07     |
| Amphetamines                             | 6.4            | 6.4             | 0.98     |
| Cannabis/marijuana                       | 39.5           | 31.8            | 0.17     |
| Nicotine/tobacco                         | 86.7           | 86.4            | 0.93     |
| Injection drug use                       | 63.4           | 58.7            | 0.41     |
| ASI composite score, mean (SE)           |                |                 |          |
| Medical problems                         | 0.14 (0.02)    | 0.16 (0.03)     | 0.51     |
| Drug use problems                        | 0.33 (0.01)    | 0.33 (0.01)     | 0.66     |
| Alcohol use problems                     | 0.08 (0.01)    | 0.03 (0.01)     | <0.01    |
| Employment problems                      | 0.55 (0.02)    | 0.58 (0.03)     | 0.39     |
| Legal problems                           | 0.17 (0.01)    | 0.10 (0.02)     | 0.01     |
| Psychiatric problems                     | 0.19 (0.01)    | 0.24 (0.02)     | 0.03     |
| Family/social problems                   | 0.07 (0.01)    | 0.11 (0.02)     | 0.02     |
| HRBS HIV risk score, mean (SE)           |                |                 |          |
| HIV total risk                           | 12.2 (0.58)    | 12.3 (0.90)     | 0.90     |
| Injection drug use risk                  | 6.9 (0.41)     | 6.9 (0.64)      | 0.98     |
| Sexual risk                              | 5.3 (0.38)     | 5.5 (0.55)      | 0.87     |
| SF-36 quality of life score, mean (SE)   |                |                 |          |
| Physical functioning                     | 82.9 (1.51)    | 83.8 (1.91)     | 0.71     |
| Role limitation due to physical health   | 56.7 (2.81)    | 60.6 (4.09)     | 0.44     |
| Role limitation due to emotional problems| 57.3 (2.94)    | 47.2 (4.31)     | 0.05     |
| Vitality/energy                          | 47.7 (1.39)    | 37.9 (2.05)     | <0.01    |
| Emotional well-being                     | 58.6 (1.35)    | 48.5 (2.03)     | <0.01    |
| Social functioning                       | 60.9 (1.83)    | 57.2 (2.72)     | 0.26     |
| Pain                                     | 62.0 (1.85)    | 56.6 (2.49)     | 0.09     |
| General health                           | 64.6 (1.44)    | 65.1 (2.04)     | 0.85     |

**Note:** P value: χ² for proportion or t-test for mean.

**Abbreviations:** SE, standard error; ASI, Addiction Severity Index; HIV, human immunodeficiency virus; HRBS, HIV Risk Behavior Scale.
Table 3 Substance use, addiction severity (ASI), HIV risk (HRBS), and quality of life (SF-36) by race and ethnicity among adult patients in opiate detoxification treatment (n = 343)

| Study variables                  | White (n = 155) | African American (n = 106) | Hispanic (n = 69) | Other (n = 13) | P valuea |
|---------------------------------|----------------|---------------------------|------------------|----------------|----------|
| Past month use, %               |                |                           |                  |                |          |
| Alcohol use to intoxication     | 18.7           | 21.7                      | 18.8             | 7.7            | 0.67     |
| Heroin                          | 82.6           | 97.2                      | 97.1             | 76.9           | <0.01    |
| Other opioids                   | 45.8           | 10.7                      | 18.8             | 38.5           | <0.01    |
| Sedatives/tranquilizers         | 37.4           | 4.4                       | 17.4             | 23.1           | <0.01    |
| Cocaine                         | 40.0           | 57.6                      | 36.2             | 30.8           | <0.01    |
| Amphetamines                    | 10.3           | 0                         | 4.3              | 7.7            | 0.01     |
| Cannabis/marijuana              | 43.2           | 35.8                      | 26.1             | 30.8           | 0.09     |
| Nicotine/tobacco                | 84.5           | 89.6                      | 91.3             | 61.5           | 0.02     |
| Injection drug use              | 69.5           | 41.9                      | 72.5             | 76.9           | <0.01    |
| ASI composite score, mean (SE)  |                |                           |                  |                |          |
| Medical problems                | 0.18 (0.02)    | 0.13 (0.03)               | 0.10 (0.03)      | 0.22 (0.09)    | 0.12     |
| Drug use problems               | 0.34 (0.01)    | 0.32 (0.01)               | 0.33 (0.01)      | 0.35 (0.02)    | 0.41     |
| Alcohol use problems            | 0.05 (0.01)    | 0.09 (0.01)               | 0.07 (0.01)      | 0.05 (0.03)    | 0.07     |
| Employment problems            | 0.47 (0.02)    | 0.72 (0.03)               | 0.54 (0.04)      | 0.47 (0.08)    | <0.01    |
| Legal problems                  | 0.14 (0.02)    | 0.16 (0.02)               | 0.16 (0.02)      | 0.11 (0.04)    | 0.59     |
| Psychiatric problems            | 0.24 (0.02)    | 0.13 (0.02)               | 0.27 (0.02)      | 0.22 (0.09)    | <0.01    |
| Family/social problems          | 0.10 (0.01)    | 0.03 (0.01)               | 0.11 (0.02)      | 0.11 (0.05)    | <0.01    |
| HRBS HIV risk score, mean (SE)  |                |                           |                  |                |          |
| HIV total risk                  | 12.6 (0.72)    | 9.0 (0.73)                | 16.2 (1.19)      | 12.7 (2.31)    | <0.01    |
| Injection drug use risk         | 7.9 (0.53)     | 4.3 (0.54)                | 8.5 (0.77)       | 7.4 (1.64)     | <0.01    |
| Sexual risk                     | 4.7 (0.45)     | 4.6 (0.52)                | 7.6 (0.80)       | 5.3 (1.29)     | <0.01    |
| SF-36 quality of life score, mean (SE) |          |                           |                  |                |          |
| Physical functioning            | 84.2 (1.77)    | 80.5 (2.12)               | 85.8 (2.68)      | 79.6 (6.50)    | 0.37     |
| Role limitation due to physical health | 56.2 (3.37)  | 59.6 (4.20)               | 60.1 (5.30)      | 53.8 (13.53)   | 0.87     |
| Role limitation due to emotional problems | 49.4 (3.68) | 60.5 (4.21)               | 53.6 (5.49)      | 61.5 (12.85)   | 0.24     |
| Vitality/energy                 | 39.6 (1.66)    | 51.2 (2.13)               | 46.3 (2.45)      | 43.1 (7.41)    | <0.01    |
| Emotional well-being            | 50.8 (1.65)    | 61.0 (2.19)               | 57.4 (2.09)      | 53.8 (8.28)    | <0.01    |
| Social functioning              | 56.2 (2.16)    | 68.5 (2.65)               | 53.4 (3.40)      | 65.4 (8.97)    | <0.01    |
| Pain                            | 56.6 (2.10)    | 62.6 (2.64)               | 60.0 (3.74)      | 55.6 (9.28)    | 0.08     |
| General health                  | 62.1 (1.69)    | 66.2 (2.33)               | 67.8 (2.27)      | 69.2 (7.00)    | 0.19     |

Note: aP value: χ² for proportion or F test for mean.

Abbreviations: SE, standard error; ASI, Addiction Severity Index; HIV, human immunodeficiency virus; HRBS, HIV Risk Behavior Scale.

level of unprotected sexual risk than whites and African Americans.

Results from adjusted regression analyses

Adjusted analyses controlling for potential confounding influences of age, years of education, marital status, employment status, and treatment modality were conducted to provide a better understanding of gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life. Variables significantly associated with gender are summarized in Table 4 and those with race/ethnicity are reported in Table 5.

Compared with men, women had a greater likelihood of using other opioids, having more psychiatric and family/social problems, and exhibiting poorer quality of life in vitality and emotional well-being. Men, on the other hand, had a greater likelihood of using heroin and reporting more alcohol use and legal problems.

African Americans had a greater likelihood than whites of using heroin and cocaine, and had more alcohol use and employment problems (Table 5). Whites had a greater likelihood than African Americans of using prescription drugs (opioids, sedatives, tranquilizers), having more psychiatric and family/social relationship problems, engaging in more total HIV risk behaviors (especially injection drug risk behaviors), and exhibiting lower quality of life in terms of role limitation, vitality, emotional well-being, and social functioning. Compared with whites, Hispanics had a lower likelihood of using marijuana and a higher likelihood of reporting better quality of life in vitality and emotional
Table 4 Summary of adjusted analyses of gender difference in substance use, addiction severity (ASI), HIV risk (HRBS), and quality of life (SF-36) among adult patients in opiate detoxification treatment (n = 343)

| Regression coefficients β (SE) from adjusted procedures* | Male versus female |
|-----------------------------------------------------------|---------------------|
| Past month substance use                                   |                     |
| Heroin                                                     | 1.3 (0.41)*         |
| Other opioids                                              | -0.9 (0.28)*        |
| ASI composite score                                         |                      |
| Alcohol use problems                                       | 0.1 (0.01)†         |
| Legal problems                                              | 0.1 (0.02)†         |
| Psychiatric problems                                       | -0.1 (0.03)†        |
| Family/social problems                                     | -0.03 (0.02)†       |
| SF-36 quality of life score                                 | 0.3 (0.10)‡         |
| Vitality/energy                                            | 0.2 (0.06)‡         |
| Emotional well-being                                       |                     |

Notes: *Adjusted linear regression analyses were conducted for continuous variables; adjusted logistic regression analyses were conducted for binary variables; each model included age, years of education, gender, racial/ethnic status, marital status, employment status, and treatment modality; †P ≤ 0.01; ‡P ≤ 0.05.

Abbreviations: SE, standard error; ASI, Addiction Severity Index; HIV, human immunodeficiency virus; HRBS, HIV Risk Behavior Scale.

well-being, but they exhibited a higher level of unprotected sexual risk. There were no significant differences between members of “other” racial/ethnic groups and whites.

Additionally, when comparing Hispanics with African Americans in the adjusted linear regression analysis, Hispanics were more likely to report a higher level of total HIV risk behaviors (regression coefficients = 0.5, P < 0.01) and injection drug use behaviors (regression coefficients = 0.7, P < 0.001). Members of “other” racial/ethnic groups also showed a higher likelihood of injection drug use behaviors than African Americans (regression coefficients = 0.7, P < 0.05). To explore whether psychiatric severity might account for racial/ethnic differences in HIV risk scores,21 we re-estimated the association between HIV risk and race/ethnicity by controlling for psychiatric severity from the Addiction Severity Index. These associations remained unchanged.

Discussion

Research has shown that patients seeking detoxification report a pervasive need for a variety of desired aftercare services (eg, employment services, self-help meetings, transportation, housing, individual or group counseling, education, medical treatment, social services, vocational training, supportive medicine, psychiatric treatment, relationship counseling, or legal assistance).22 However, many opioid-dependent patients receive detoxification treatment only, and repeated admissions for detoxification treatment are common.24,25 This multisite national study of patients seeking opioid detoxification identifies differential treatment needs for various groups, and the results are useful for informing aftercare and need-service matching interventions to improve care for the growing, diverse opioid-dependent population, and for possibly reducing emergency room and other high-cost medical services by tailoring treatment to specific patient needs.

Clinical studies of gender differences have focused mainly on cocaine-dependent patients or patients with different drug dependences.24-27 Generalizability of results from these studies to opioid-dependent patients is limited and complicated by small sample sizes, descriptive results, or a different drug-use focus. These studies show mixed results in pattern of drug use, but generally suggest greater drug-related problems in women than in men. The present study adds new data to the literature of opioid dependence by examining a geographically diverse sample recruited from 12 sites and by applying adjusted procedures to make direct comparisons between genders and racial/ethnic groups for multiple clinical indicators. Our results revealed that women used more nonheroin opioids and had more psychiatric and family/social relationship problems, while men used more heroin and reported more problems related to alcohol use and criminal activities. Additionally, women resembled men in HIV risk scores, but women reported poorer quality of life.

These discrete patterns emphasize the need for gender-specific psychosocial interventions in addition to standard treatment for opioid dependence to improve treatment retention and response.28-31 For example, relationship or mental health problems, as well as childcare or transportation concerns, may be more likely to interfere with women’s treatment use than that for men; thus, women can benefit from ancillary services tailored to address these issues.29-31 For men, treatment could incorporate motivational interviewing to address alcohol use problems or legal services to assist with legal problems. Of note, recent research has shown the benefits of male-targeted interventions in addressing motivation, communication skills, sexuality, or HIV risk.32,33 Clearly, this understudied area warrants more research to develop male-specific interventions tailored to men’s unique areas of concern. Furthermore, quality of life has increasingly been considered a crucial outcome measure in addiction treatment trials.5 The finding of poor quality of life in women indicates that baseline measures of quality of life should be included as a control variable in the analysis of treatment response to mitigate its confounding effects.
Table 5  Summary of adjusted analyses of racial/ethnic differences in substance use, addiction severity (ASI), HIV risk (HRBS), and quality of life (SF-36) among adult patients in opiate detoxification treatment (n = 343)

| Regression coefficients | African American versus white | Hispanic versus white |
|-------------------------|-------------------------------|----------------------|
| Past month substance use |                               |                      |
| Heroin                  | 1.6 (0.68) ^a                 | 1.4 (0.79)           |
| Other opioids           | −1.8 (0.41) ^c                | −1.1 (0.39)          |
| Sedatives/tranquilizers | −2.0 (0.52) ^c                | −0.7 (0.40)          |
| Cocaine                 | 0.7 (0.31) ^b                 | −0.3 (0.32)          |
| Cannabis/marijuana      | −0.2 (0.32) ^c                | −1.0 (0.36) ^d       |
| Injection drug use       | −1.3 (0.33) ^d                | −0.2 (0.36)          |
| ASI composite score     |                               |                      |
| Alcohol use problems    | 0.04 (0.02) ^a                | 0.03 (0.02)          |
| Employment problems     | 0.2 (0.03) ^c                 | 0.04 (0.04)          |
| Psychiatric problems    | −0.1 (0.03) ^c                | 0.04 (0.03)          |
| Family/social problems  | −0.04 (0.02) ^c               | 0.02 (0.02)          |
| HRBS HIV risk score     |                               |                      |
| HIV total risk ^e        | −0.4 (0.14) ^c                | 0.1 (0.15)           |
| Injection drug use risk  | −0.7 (0.16) ^d                | −0.03 (0.17)         |
| Sexual risk ^c           | 0.1 (0.15)                    | 0.4 (0.16) ^d        |
| SF-36 quality of life score |                         |                      |
| Role limitation due to emotional problems | 0.8 (0.31) ^c | −0.01 (0.33)         |
| Vitality/energy         | 0.4 (0.12) ^c                 | 0.3 (0.13) ^c        |
| Emotional well-being    | 0.2 (0.08) ^c                 | 0.2 (0.08) ^c        |
| Social functioning       | 0.2 (0.11) ^c                 | −0.2 (0.12)          |

Notes: Adjusted linear regression analyses were conducted for continuous variables; adjusted logistic regression analyses were conducted for binary variables; each model included age, years of education, gender, racial/ethnic status, marital status, employment status, and treatment modality; ^a P < 0.05; ^b P < 0.01; ^c P < 0.001; ^d (SE); HIV total risk score for Hispanics versus African Americans = 0.5 (0.17); ^e injection drug use risk score for Hispanics versus African Americans = 0.7 (0.19); ^f injection drug use risk score for members of other race/ethnicity versus African Americans = 0.7 (0.34). ^g

Abbreviations: SE, standard error; ASI, Addiction Severity Index; HIV, human immunodeficiency virus; HRBS, HIV Risk Behavior Scale.

The results also highlight significant public health concerns for whites and Hispanics. Whites not only had a greater likelihood of using prescription drugs (than African Americans) and cannabis (than Hispanics) and of engaging in more risky injection drug use (than African Americans), but they also showed more psychiatric and family/social relationship problems (than African Americans) and poorer quality of life (than African Americans and Hispanics). Although African Americans used more heroin and cocaine than whites and experienced greater employment problems than whites, they reported lower levels of risky injection drug use (than whites and Hispanics) and exhibited better mental health and social functioning (than whites). Thus, whites show more psychopathology and HIV risk than African Americans. Our additional analyses did not find the impact of psychiatric severity on HIV risk scores, suggesting that the association between race/ethnicity and HIV risk behaviors is robust.

These findings of an elevated level of HIV-related injection drug use risk among whites are worrisome because recent evidence has suggested a growing rate of injection drug use in young white adults, and young injection drug users generally engage in a high level of risky injection and sexual behaviors. Further, opioid addiction and drug-related problems may be more detrimental to whites’ social support, family functioning, and mental health than to those of African Americans. Bourgois et al have reported that, although African American heroin users generally have a more pervasive history of incarceration than white users, they often have maintained long-term ties with their families. In contrast, white heroin users are more likely than African American users to be expelled from their families and to perceive themselves as being defeated by addiction as their problems escalate. This study also reveals a better quality of life and family/social functioning among African Americans than among whites.

Taken together, whites may benefit from interventions tailored not only to their risky injection drug use, but also to issues related to psychiatric problems, social support, and family problems. For African Americans, their higher level of employment problems than whites may be related in part to earlier or prevalent involvement with illicit drugs (heroin or cocaine) and the criminal justice system, thereby potentially hindering educational attainment. This distinct pattern of greater employment problems and cocaine...
use among African Americans has important implications for intervention. For instance, greater addiction severity, employment problems, cocaine use, and African American race have been found to be associated with an increased rate of attrition from methadone maintenance treatment programs. Therefore, the provision of additional vocational services or supportive employment counseling, in addition to standard treatment for opioid dependence, can be useful in improving both employment and substance use problems.

The last issue concerns Hispanics’ elevated level of HIV risk behaviors in both risky injection drug use (greater than African Americans) and unprotected sexual behaviors (greater than whites). Regardless of gender, the rate of new HIV infections among Hispanics in the US is about 2–4 times higher than that of whites. HIV obviously has become a serious threat to Hispanics in the US. Unfortunately, HIV-related interventions have faced many unique challenges because Hispanics as a group in the US are considerably diverse in their cultural backgrounds. Their comparatively high rates of poverty, low education, and lack of insurance, along with language barriers, immigration issues, and diverse cultural beliefs about sexuality, have further impeded HIV prevention and treatment efforts. Consequently, Hispanics have a comparatively low rate of HIV testing and a high rate of late HIV diagnosis. These findings clearly highlight the need for research to monitor and discern patterns of HIV risk behaviors continuously and to develop culturally and linguistically appropriate HIV risk reduction interventions to meet the diverse needs of Hispanics.

This study has some limitations. The results are based on treatment-seeking opioid-dependent adults who participated in Clinical Trials Network studies. The sample is not necessarily representative of all opioid-dependent patients. Another limitation is reliance on patients’ self-reports, which are subject to recall or reporting bias. Nonetheless, studies have found that self-reported drug use patterns and HIV-related injection and sexual behaviors among drug users are generally reliable. In addition, due to confidentiality concerns, information on study sites was removed from the deidentified data files used for this research, and was not included in the analysis. Lastly, the small sample size of the “other” racial/ethnic group constrains the power to compare clinical characteristics of this group with those of whites, African Americans, or Hispanics.

Nonetheless, the multisite studies of the Clinical Trials Network also have noteworthy strengths not available from studies of participants from a single site. The participants were recruited from 12 major treatment programs at two treatment modalities across the nation, making them more generalizable than those found in single-site studies. All participants were assessed by an identical set of standardized instruments (Addiction Severity Index, HIV Risk Behavior Scale, SF-36) with demonstrated reliability and validity in clinical samples to allow for comparisons across treatment settings.

Conclusion
These results highlight distinct clinical needs for different gender and racial/ethnic groups among opioid-dependent patients when presenting for detoxification. First, the more severe pattern of psychopathology among women and whites emphasizes the need to monitor an increased trend of opioid addiction and treatment use in these two groups and to develop effective combined psychosocial and pharmacologic treatments for opioid addiction to meet the diverse needs of the expanding opioid-abusing population (eg, enhancing treatment retention and reducing use of emergency department or inpatient care). Specifically, due to an increased rate of opioid addiction and the availability of office-based buprenorphine treatment, ie, Suboxone® and Subutex® (Reckitt Benckiser Pharmaceuticals, Inc), use of buprenorphine for either short-term detoxification or maintenance treatment is expected to increase over time. Therefore, research is obviously needed to develop and incorporate effective comprehensive interventions to improve detoxification patients’ use of continuing care or rehabilitation services.

Finally, it is important to note that methadone treatment (detoxification or maintenance) remains the primary medication-assisted opioid therapy for opioid addiction in the US. Per the survey data of March 31, 2008, an estimated 268,071 clients (98.4%) in facilities with opioid treatment programs received methadone compared with 4280 clients (1.6%) who received buprenorphine. Methadone maintenance treatment not only reduces illicit opioid use, HIV risk behaviors, and drug-related criminal behaviors, but is also associated with lower rates of utilizing costly health care (eg, emergency services, inpatient visits, and other medical services) by individuals with opioid addiction. While both buprenorphine and methadone treatment are clinically effective and cost-effective, methadone treatment is superior to buprenorphine at fixed medium or high doses and appears to be the preferred treatment by some individuals with severe addiction profiles.
Gender and racial differences in adult opioid detoxification

and ease of clinical administration are likely to recruit increasing numbers of individuals into treatment (eg, those with less prolonged opioid addiction, and women who are hesitant to use methadone treatment because of childcare or transportation barriers).\(^{5,49,55}\) Clearly, research is needed to elucidate opioid-dependent individuals’ preferences for buprenorphine versus methadone treatment and their safety profiles (eg, buprenorphine and benzodiazepine interaction) and effectiveness to optimize treatment response for diverse gender and racial/ethnic groups.

Acknowledgments

This article was made possible by grants from the US National Institute on Drug Abuse of the National Institutes of Health. (DA027503, DA019623, and DA019901 to LTW; DA026652 to WWE; DA013045 to WL; HHSN271200522071C to DGB; DA017009 and DA013043 to GEW). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. We thank Amanda McMillan for her editorial assistance and the three reviewers for their valuable comments.

Disclosure

WL has received research funding from Titan Pharmaceuticals, Reckitt Benckiser, and Hythiam; he has served as a member of the Advisory Board for the US World Meds. GEW is a member of the RADARS(r) System Scientific Advisory Board which assesses abuse, misuse, and diversion of prescription medications. Denver Health and Hospital Authority is a nonprofit public hospital that administers the RADARS(r) system, and its costs are supported by contracts with pharmaceutical companies.

References

1. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009.
2. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618–627.
3. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights – 2007 National Admissions to Substance Abuse Treatment Services. OAS Series #S-45, HHS Publication No. (SMA) 09-4360. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009.
4. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–1943.
5. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155–166.
6. Wu LT, Woody GE, Yang C, Blazer DG. How do prescription opioid users differ from users of heroin or other drugs in psychopathology: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med. In press.
7. Sullivan LE, Chawarski M, O’Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005;79(1):113–116.
8. Ling W, Amass L, Shoptaw S, et al; Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100(8):1090–1100.
9. Cicero TJ, Lynskey M, Todorov A, Inciardi JA, Surratt HL. Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain. 2008;139(1):127–135.
10. Green TC, Grimes Serrano JM, Licitra A, Budman SH, Butler SF. Women who abuse prescription opioids: Findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend. 2009;103(1–2):65–73.
11. Broz D, Ouellet LJ. Racial and ethnic changes in heroin injection in the United States: Implications for the HIV/AIDS epidemic. Drug Alcohol Depend. 2008;94(1–3):221–233.
12. Mark TL, Dilonardo JD, Chalk M, Coffey RM. Trends in inpatient detoxification services, 1992–1997. J Subst Abuse Treat. 2002;23(4):253–260.
13. Mark TL, Dilonardo JD, Chalk M, Coffey R. Factors associated with the receipt of treatment following detoxification. J Subst Abuse Treat. 2003;24(4):299–304.
14. Mark TL, Vandivort-Warrn R, Montejano LB. Factors affecting detoxification readmission: Analysis of public sector data from three states. J Subst Abuse Treat. 2006;31(4):439–445.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
16. McGahan PL, Griffith JA, Parante R, McLellan AT. Composite Scores from the Addiction Severity Index. Washington, DC: National Institute on Drug Abuse Project DA02554 and the Veterans Administration; 1982.
17. McLellan AT, Luborsky L, Cacciola J, et al. New data from the Addiction Severity Index: Reliability and validity in three centers. J Nerv Ment Dis. 1985;173(7):412–423.
18. Darke S, Hall W, Heather N, Ward J, Wodak A. The reliability and validity of a scale to measure HIV risk-taking behavior among intravenous drug users. AIDS. 1991;5(2):181–185.
19. Petry NM. Reliability of drug users’ self-reported HIV risk behaviors using a brief, 11-item scale. Subst Use Misuse. 2001;36(12):1731–1747.
20. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
21. Metzger D, Woody G, de Philippis D, McLellan AT, O’Brien CP, Platt JJ. Risk factors for needle sharing among methadone-treated patients. Am J Psychiatry. 1991;148(5):636–640.
22. Tuten M, Jones HE, Lertch EW, Stitzer ML. Aftercare plans of inpatients undergoing detoxification. Am J Drug Alcohol Abuse. 2003;29(3):547–555.
23. Lundgren LM, Sullivan L, Amodeo M. How do treatment repeaters use the drug treatment system? An analysis of injection drug users in Massachusetts. J Subst Abus Treat. 2006;30(2):121–128.
24. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. J Subst Abus Treat. 2004;79(1):265–272.
25. Wong CJ, Badger GJ, Sigmon SC, Higgins ST. Examining possible gender differences among cocaine-dependent outpatients. Exp Clin Psychopharmacol. 2002;10(3):316–323.
26. Najavits LM, Lester KM. Gender differences in cocaine dependence. Drug Alcohol Depend. 2008;97(1–2):190–194.
27. Lejuez CW, Bornovalova MA, Reynolds Ek, Daughters SB, Curtin JJ. Risk factors in the relationship between gender and crack/cocaine. Exp Clin Psychopharmacol. 2007;15(2):165–175.
28. Amato L, Minezzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2008;(4):CD005031.
29. Smith BD, Marsh JC. Client-service matching in substance abuse treatment for women with children. J Subst Abuse Treat. 2002;22(3):161–168.
30. Greenfield SF, Brooks AJ, Gordon SM, et al. Substance abuse treatment entry, retention, and outcome in women: A review of the literature. Drug Alcohol Depend. 2007;86(1):1–21.
31. Marsh JC, Cao D, Guerrero E, Shin HC. Need-service matching in substance abuse treatment: Racial/ethnic differences. Eval Program Plan. 2009;32(1):43–51.
32. Bartholomew NG, Hiller ML, Knight K, Nucatola DC, Simpson DD. Effectiveness of communication and relationship skills training for men in substance abuse treatment. J Subst Abuse Treat. 2000;18(3):217–225.
33. Calsyn DA, Hatch-Maillette M, Tross S, et al. Motivational and skills training in substance abuse treatment. J Subst Abuse Treat. 2009;37(2):138–150.
34. Rondinelli AJ, Ouellet LJ, Strathdee SA, et al. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009;104(1–2):167–174.
35. Bourgois P, Martinez A, Kral A, Edlin BR, Schonberg J, Ciccarone D. Reinterpreting ethnic patterns among white and African-American men who inject heroin: A social science of medicine approach. PLoS Med. 2006;3(10):e452.
36. Brown ES, Tirado C, Minahuddin A, et al. Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side effects during buprenorphine therapy. J Etnh Subst Abuse. 2010;9(2):106–114.
37. Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004;74(2):177–185.
38. Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth BM. Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse. 2010;36(3):155–160.
39. Kemp K, Savitz B, Thompson W, Zanis DA. Developing employment services for criminal justice clients enrolled in drug user treatment programs. Subst Use Misuse. 2004;39(13–14):2491–2511.
40. Shepard DS, Reif S. The value of vocational rehabilitation in substance user treatment: A cost-effectiveness framework. Subst Use Misuse. 2004;39(13–14):2581–2609.
41. Centers for Disease Control and Prevention. HIV in the United States. Available at: http://www.cdc.gov/hiv/resources/factsheets/PDF/us.pdf. Accessed Oct 8 2010.
42. Centers for Disease Control and Prevention. HIV/AIDS among Hispanics/Latinos. Available at: http://www.cdc.gov/hiv/hispanics/resources/factsheets/pdf/hispanic.pdf. Accessed Oct 8 2010.
43. Garland JM, Andrade AS, Page KR. Unique aspects of the care of HIV-positive Latino patients living in the United States. Curr HIV/AIDS Rep. 2010;7(3):107–116.
44. Darke S. Self-report among injecting drug users: A review. Drug Alcohol Depend. 1998;51(3):253–63; discussion 267–268.
45. Goldstein MF, Friedman SR, Neaigus A, Jose B, Ildefonso G, Curtis R. Self-reports of HIV risk behavior by injecting drug users: Are they reliable? Addiction. 1995;90(8):1097–1104.
46. McElrath K, Chitwood DD, Griffin DK, Comerford M. The consistency of self-reported HIV risk behavior among injection drug users. Am J Public Health. 1994;84(12):1965–1970.
47. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171, iii–iv.
48. Aiken KL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse Treat. 2010;39(2):96–104.
49. Ling W, Smith D. Buprenorphine: Blending practice and research. J Subst Abuse Treat. 2002;23(2):87–92.
50. Substance Abuse and Mental Health Services Administration. The N-SSATS Report: Overview of Opioid Treatment Programs within the United States: 2008. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2010.
51. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction. 1998;93(4):515–532.
52. McCarty D, Perrin NA, Green CA, et al. Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug Alcohol Depend. 2010;111(3):235–240.
53. Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: A mixed treatment comparison meta-analysis. Drug Alcohol Depend. 2010;108(1–2):110–114.
54. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
55. Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT Trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340–352.